LLY241018P920000
- 12.81
- +7.41+137.22%
Eli Lilly and Co Newsroom
An AI Robot Trader Dumped the King of AI Chips. What It Picked Instead.
Moderna Continues to Be the Most Shorted S&P 500 Healthcare Stock in September
Eli Lilly's Zepbound to Undergo First-of-its-kind Study on Economic Impact
Eli Lilly and Co's major move! Can obesity drugs become the "employment magic weapon" in the United Kingdom?
①Eli Lilly and Co will initiate "real world research", that is, collecting patient-related data in real world settings to provide information to the united kingdom's national medical services system; ②United kingdom Health Minister Wes Strein said that this collaboration is "key to building a healthier society, a healthier economy, and making the NHS fit for the future".
Eli Lilly Unusual Options Activity
"Trump Organization" stock price rose in pre-market trading, with mixed movements in the three major US stock index futures. | Tonight's focus
①Trump Media Technology Group rose nearly 9% in pre-market trading; ②Alibaba fell more than 4%, JD.com fell more than 6%; ③Wolfspeed is set to receive a $0.75 billion grant from the US Department of Commerce; ④Eli Lilly and Co is establishing the China Medical Innovation Center and Innovation Incubator in Beijing.
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $990 to $1,050
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Eli Lilly: A Strong Buy on Robust Revenue Growth and Expanding Market Potential
FDA 'Three Reflections' removed eli lilly and co (LLY.US) weight loss drug from the shortage list, Hims & Hers Health (HIMS.US) promptly rose by 10%.
After the FDA decided to remove Eli Lilly and Co's tirzepatide from the list of pharmaceutical shortages, a lawsuit related to this delisting caused Hims & Hers Health (HIMS.US) to rise on Monday, closing up about 10%.
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Hims +6% Monday After FDA Said it Might Halt Hims Weight Loss Drug Sales Friday
Eli Lilly's (NYSE:LLY) Crohn's Disease Drug Outperforms JNJ's Version
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
Lilly Reports Positive Data for Omvoh Versus Stelara in Crohn's
Amgen's stock price has dropped, analysts warn that the speculation on weight loss drugs has already been digested by the market.
Amgen Inc.'s stocks fell on Monday after an analyst no longer holds a bullish view on this biotechnology giant, citing concerns that investor optimism about a candidate obesity drug has been reflected in the stock price, with more downside risks than upside opportunities. Truist analyst Srikripa Devarakonda downgraded the stock from buy for the past 11 months to hold. However, she raised the target price from $320 to $333, but the new target price is only 1.4% higher than last Friday's closing price. The stock traded down 1.1% in pre-market trading, following a rise last Friday
'Most Widely Hated' Bull Market Reaches 2-Year Milestone: Top 20 S&P 500 Stocks Driving The Rally
Eli Lilly and Company (LLY): Growth Driven by Patents and Pipeline Milestones
Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.